Bellicum Pharmaceuticals (NASDAQ:BLCM) will announce its second quarter 2020 financial results on August 6, 2020, after U.S. market close. A conference call and webcast will follow at 5 p.m. ET/2 p.m. PT to discuss results and provide a corporate update. Bellicum focuses on controllable cellular immunotherapies aimed at cancer treatment, with product candidates like GoCAR-T® designed to enhance CAR-T cell efficacy. More details can be found on their official website.
Bellicum Pharmaceuticals (NASDAQ:BLCM) announced FDA clearance for its investigational new drug application (IND) for BPX-603, a GoCAR-T® candidate targeting HER2-expressing solid tumors. This clearance adds a second clinical program leveraging Bellicum's novel technology to enhance CAR-T cell efficacy. The company plans to initiate a Phase 1/2 trial later this year, aiming to improve antitumor activity through its dual-switch technology. This is a strategic milestone in the company's efforts to develop controllable cell therapies.
Bellicum Pharmaceuticals (NASDAQ:BLCM) announced equity inducement grants for a new employee, comprising 16,820 stock options at an exercise price of $7.63 per share. Approved by the Compensation Committee, the grants are effective as of May 29, 2020, and will vest over four years, with 25% vesting after one year. The stock options are in accordance with Nasdaq Listing Rule 5635(c)(4) and the Company's 2019 Equity Incentive Plan. Bellicum focuses on developing controllable cellular immunotherapies for cancers, with its lead candidate BPX-601 designed for enhanced efficacy in CAR-T therapies.
Bellicum Pharmaceuticals (NASDAQ:BLCM) announced its participation in two virtual investor conferences. The first is the Jefferies Virtual Healthcare Conference, scheduled for June 3, 2020, at 4:00 p.m. EDT, featuring a fireside chat format. The second is the Investor Summit Virtual Summer Summit on June 10, 2020, at 3:20 p.m. EDT, in a presentation format. Live webcasts will be available on Bellicum's website, with archived versions accessible post-event. Bellicum specializes in controllable cellular immunotherapies, aiming to enhance CAR-T and CAR-NK cell therapies.
Summary not available.